NO20092370L - Nye intermeditater og fremgangsmate anvendelig i fremstillingen av {2-[1-(3,5-bis-tri-fluormetyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanon - Google Patents
Nye intermeditater og fremgangsmate anvendelig i fremstillingen av {2-[1-(3,5-bis-tri-fluormetyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanonInfo
- Publication number
- NO20092370L NO20092370L NO20092370A NO20092370A NO20092370L NO 20092370 L NO20092370 L NO 20092370L NO 20092370 A NO20092370 A NO 20092370A NO 20092370 A NO20092370 A NO 20092370A NO 20092370 L NO20092370 L NO 20092370L
- Authority
- NO
- Norway
- Prior art keywords
- pyridin
- chlorophenyl
- docket number
- font
- triazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Det er beskrevet nye forbindelser, (2-klorfenyl)-[2-(2-hydroksy-2-pyridin-4-yl-vinyl)pyridin-3-yl]metanonbenzoat, og (2-klorfenyl)-[2-(2-hydroksy-2-pyridin-4-yl-vinyl)pyridin-3-yl]metanontoluat, som er nyttige mellomprodukter for fremstillingen av forbindelsen av Formel I:TEXT: (I) Det er videre beskrevet nye fremgangsmåter for fremstilling av en krystallinsk forbindelse, som er {2-[1-(3,5-bis-trifluormetyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanon, Form IV.The following margins are utilized with size A4 paper in order to comply generally with worldwide formatting requirements:Top: 1.5" Bottom: 1" Left: 1.25" Right: 1" Header: 0.4" The docket number and the page number should be indicated in the header. The page number should be a few lines below the docket number because when a PCT application publishes, the docket number is cut off and the publication number is printed at the top. Font for newly-created applications should be Times New Roman. Do not change the font if re-using or copying text from previously created documents. This will eliminate the real possibility of damaging ISIS imports, structures, symbols, etc. Tables too large to be portrayed in portrait view may be placed in landscape view; however, the docket number and page numbers must in the same location as the rest of the specification. If necessary, the font size of tables may be reduced to 10.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87085106P | 2006-12-20 | 2006-12-20 | |
| PCT/US2007/086319 WO2008079600A1 (en) | 2006-12-20 | 2007-12-04 | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20092370L true NO20092370L (no) | 2009-09-16 |
Family
ID=39273082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20092370A NO20092370L (no) | 2006-12-20 | 2009-06-22 | Nye intermeditater og fremgangsmate anvendelig i fremstillingen av {2-[1-(3,5-bis-tri-fluormetyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanon |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US8772496B2 (no) |
| EP (1) | EP2121610B1 (no) |
| JP (1) | JP5443168B2 (no) |
| KR (1) | KR20090081028A (no) |
| CN (1) | CN101568523A (no) |
| AU (1) | AU2007337255A1 (no) |
| BR (1) | BRPI0721069A2 (no) |
| CA (1) | CA2671770C (no) |
| DK (1) | DK2121610T3 (no) |
| EA (1) | EA200970604A1 (no) |
| EC (1) | ECSP099441A (no) |
| ES (1) | ES2471990T3 (no) |
| HR (1) | HRP20140613T1 (no) |
| IL (1) | IL198775B (no) |
| MX (1) | MX2009006636A (no) |
| NO (1) | NO20092370L (no) |
| PL (1) | PL2121610T3 (no) |
| PT (1) | PT2121610E (no) |
| RS (1) | RS53386B (no) |
| SI (1) | SI2121610T1 (no) |
| WO (1) | WO2008079600A1 (no) |
| ZA (1) | ZA200903578B (no) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200970604A1 (ru) * | 2006-12-20 | 2009-10-30 | Эли Лилли Энд Компани | Новое промежуточное соединение и способ, используемый для получения {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона |
| US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
| DK3265087T3 (da) | 2015-03-04 | 2020-10-19 | Vanda Pharmaceuticals Inc | Fremgangsmåde til behandling med tradipitant |
| WO2017031215A1 (en) * | 2015-08-17 | 2017-02-23 | Eli Lilly And Company | Process development of a pyridine-containing nk-1 receptor antagonist |
| US11549147B2 (en) | 2017-09-13 | 2023-01-10 | Vanda Pharmaceuticals Inc. | Treatment of atopic dermatitis with tradipitant |
| AU2018367623B2 (en) | 2017-11-17 | 2024-03-28 | Vanda Pharmaceuticals Inc. | Method of treatment of gastrointestinal diseases with tradipitant |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| WO2020117811A1 (en) | 2018-12-03 | 2020-06-11 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| WO2021195205A1 (en) * | 2020-03-26 | 2021-09-30 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE384053T1 (de) * | 2002-04-26 | 2008-02-15 | Lilly Co Eli | Triazolderivate als tachykininrezeptor- antagonisten |
| US7381826B2 (en) * | 2003-10-24 | 2008-06-03 | Eli Lilly And Company | Crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| WO2006083711A1 (en) * | 2005-02-01 | 2006-08-10 | Eli Lilly And Company | Tachykinin receptor antagonists |
| EA200970604A1 (ru) * | 2006-12-20 | 2009-10-30 | Эли Лилли Энд Компани | Новое промежуточное соединение и способ, используемый для получения {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона |
-
2007
- 2007-12-04 EA EA200970604A patent/EA200970604A1/ru unknown
- 2007-12-04 CA CA2671770A patent/CA2671770C/en active Active
- 2007-12-04 RS RS20140349A patent/RS53386B/en unknown
- 2007-12-04 AU AU2007337255A patent/AU2007337255A1/en not_active Abandoned
- 2007-12-04 PT PT78651379T patent/PT2121610E/pt unknown
- 2007-12-04 PL PL07865137T patent/PL2121610T3/pl unknown
- 2007-12-04 US US12/515,794 patent/US8772496B2/en active Active
- 2007-12-04 EP EP07865137.9A patent/EP2121610B1/en active Active
- 2007-12-04 MX MX2009006636A patent/MX2009006636A/es active IP Right Grant
- 2007-12-04 JP JP2009543027A patent/JP5443168B2/ja active Active
- 2007-12-04 ES ES07865137.9T patent/ES2471990T3/es active Active
- 2007-12-04 SI SI200731483T patent/SI2121610T1/sl unknown
- 2007-12-04 BR BRPI0721069-8A patent/BRPI0721069A2/pt not_active Application Discontinuation
- 2007-12-04 WO PCT/US2007/086319 patent/WO2008079600A1/en active Application Filing
- 2007-12-04 DK DK07865137.9T patent/DK2121610T3/da active
- 2007-12-04 KR KR1020097012894A patent/KR20090081028A/ko not_active Application Discontinuation
- 2007-12-04 CN CNA2007800466993A patent/CN101568523A/zh active Pending
-
2009
- 2009-05-14 IL IL198775A patent/IL198775B/en active IP Right Grant
- 2009-05-22 ZA ZA200903578A patent/ZA200903578B/xx unknown
- 2009-06-17 EC EC2009009441A patent/ECSP099441A/es unknown
- 2009-06-22 NO NO20092370A patent/NO20092370L/no not_active Application Discontinuation
-
2014
- 2014-03-27 US US14/227,857 patent/US20140206877A1/en not_active Abandoned
- 2014-06-27 HR HRP20140613TT patent/HRP20140613T1/hr unknown
-
2015
- 2015-11-10 US US14/937,051 patent/US9708291B2/en active Active
-
2017
- 2017-06-15 US US15/623,550 patent/US10035787B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160060250A1 (en) | 2016-03-03 |
| ZA200903578B (en) | 2010-07-28 |
| US20100056795A1 (en) | 2010-03-04 |
| EA200970604A1 (ru) | 2009-10-30 |
| EP2121610A1 (en) | 2009-11-25 |
| EP2121610B1 (en) | 2014-04-02 |
| HRP20140613T1 (hr) | 2014-08-15 |
| CA2671770C (en) | 2015-09-15 |
| JP5443168B2 (ja) | 2014-03-19 |
| PT2121610E (pt) | 2014-06-25 |
| WO2008079600A1 (en) | 2008-07-03 |
| US20170283394A1 (en) | 2017-10-05 |
| US9708291B2 (en) | 2017-07-18 |
| JP2010513546A (ja) | 2010-04-30 |
| IL198775A0 (en) | 2010-02-17 |
| CN101568523A (zh) | 2009-10-28 |
| SI2121610T1 (sl) | 2014-08-29 |
| DK2121610T3 (da) | 2014-06-30 |
| ECSP099441A (es) | 2009-07-31 |
| US10035787B2 (en) | 2018-07-31 |
| CA2671770A1 (en) | 2008-07-03 |
| KR20090081028A (ko) | 2009-07-27 |
| US20140206877A1 (en) | 2014-07-24 |
| US8772496B2 (en) | 2014-07-08 |
| PL2121610T3 (pl) | 2014-09-30 |
| AU2007337255A1 (en) | 2008-07-03 |
| BRPI0721069A2 (pt) | 2014-02-04 |
| ES2471990T3 (es) | 2014-06-27 |
| RS53386B (en) | 2014-10-31 |
| IL198775B (en) | 2018-08-30 |
| MX2009006636A (es) | 2009-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20092370L (no) | Nye intermeditater og fremgangsmate anvendelig i fremstillingen av {2-[1-(3,5-bis-tri-fluormetyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanon | |
| NZ594537A (en) | Compounds, compositions, and methods for preventing metastasis of cancer cells | |
| RU2454415C9 (ru) | Производное индола | |
| NZ601316A (en) | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates | |
| JP2007092033A5 (no) | ||
| PE20131118A1 (es) | Derivados de heteroarilpiperidina y piperazina como fungicidas | |
| NZ595553A (en) | VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol | |
| JP2013514345A5 (no) | ||
| WO2007081569A3 (en) | Cetp inhibitors | |
| ATE496027T1 (de) | Oximester-fotoinitiatoren | |
| JP2014507464A5 (no) | ||
| WO2005037781A3 (fr) | Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
| HK1184147A1 (en) | Crystalline(r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h- indazol-3-yl)vinyl)-1h-pyrazol-1-yl) ethanol and its use as fgfr inhibitor ((r)-(e)-2-(4-(2-(5-(1-(35--4-))-1h--3-) )-1h--1-) fgfr | |
| JP2009533410A5 (no) | ||
| NZ601408A (en) | Novel 3-hydroxy-5-arylisothiazole derivative | |
| JP2009532453A5 (no) | ||
| PE20190345A1 (es) | Combinaciones de compuestos activos | |
| NZ581698A (en) | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer | |
| DE60112933D1 (de) | N-phenyl-4-(4-pyridyl)-2-pyrimidinamine-derivate | |
| JP2013507434A5 (no) | ||
| MX2007007956A (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| NO20083390L (no) | Piperaziner og piperidiner som mGluR5-forsterkere | |
| BR112012007069A2 (pt) | derivado de fenol | |
| NO20085269L (no) | 2-tioksantinderivater som fungerer som MPO-inhibitorer | |
| RS54146B1 (en) | CIKLOPENTILAKRILAMIDA DERIVATIVES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |